<p>在过去的 7 天里，美国市场下跌了 2.3%，但在过去一年中仍上涨了 13%，预计年收益增长将达到 16%。在这种背景下，识别高增长科技股需要寻找那些展现出强大创新能力和适应能力的公司，使其在波动的市场环境中占据有利位置。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.02%</td>
<td>31.25%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.20%</td>
<td>27.96%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>30.23%</td>
<td>46.19%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ondas</td>
<td>35.55%</td>
<td>69.51%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.90%</td>
<td>48.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.76%</td>
<td>155.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>12.08%</td>
<td>99.98%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 73 只股票的完整列表。</p>
<p>让我们深入探讨筛选器中的一些优质选择。</p>
<h2>Protagonist Therapeutics (PTGX)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Protagonist Therapeutics, Inc. 是一家总部位于美国的发现与开发公司，市值为 62.9 亿美元。</p>
<p><strong>运营：</strong> Protagonist Therapeutics 专注于生物技术，从该领域产生的收入为 4602 万美元。</p>
<p>Protagonist Therapeutics 预计将在三年内从亏损转向盈利，年利润增长预期为 40.85%。这一转变得益于预计年收入增长 23.6%，超过美国市场平均 10.4% 的水平。最近，FDA 对 rusfertide 和 ICOTYDE(TM) 的批准突显了其在应对复杂医疗条件（如真性红细胞增多症和斑块性银屑病）方面的创新优势，可能设定新的行业标准并增强其市场地位。尽管在其第四季度财报中记录了 4438 万美元的净亏损，但这些战略产品的进展可能会催化转机，提升其在生物技术领域的竞争地位。</p>
<ul>
<li>在本健康报告中解锁我们对 Protagonist Therapeutics 股票分析的全面见解。</li>
<li>在我们的历史部分探索历史数据，以跟踪 Protagonist Therapeutics 的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 3 月 PTGX 的收益和收入增长</p>
<h2>Everpure (PSTG)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Everpure, Inc. 专注于全球数据存储和管理技术、产品及服务，市值约为 212.8 亿美元。</p>
<p><strong>运营：</strong> Everpure, Inc. 从其计算机存储设备部门获得约 36.6 亿美元的收入，专注于在美国和国际上提供数据存储和管理解决方案。</p>
<p>Everpure 最近的战略举措强调了其增强人工智能基础设施能力的承诺，这对维持在科技行业的竞争力至关重要。Everpure 推出了 Evergreen//One for FlashBlade//EXA 和即将推出的 Everpure Data Stream 测试版，旨在减少企业人工智能项目的复杂性和成本。这些创新旨在简化从数据摄取到推理的数据处理，通过自动化数据移动显著加快结果时间。这种方法不仅简化了人工智能部署的操作方面，还确保在大规模应用中始终满足高性能标准，FlashBlade//EXA 在 SPECstorage Solution 2020 和 MLPerf 测试中的创纪录基准分数就是明证。通过与 NVIDIA 的模块化 STX 参考架构对齐，Everpure 准备满足下一代人工智能工厂日益增长的需求，确保其解决方案始终处于技术进步的前沿，同时支持可持续增长。</p>
<ul>
<li>在我们的健康报告中更深入地了解 Everpure 的潜力。</li>
<li>通过我们的详细历史表现报告评估 Everpure 的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 3 月 PSTG 的收益和收入增长</p>
<h2>Clear Secure (YOU)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Clear Secure, Inc. 在美国主要运营一个安全身份平台，品牌名称为 CLEAR，市值约为 71.3 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其安全生物识别身份验证部门产生收入，该部门贡献了 9.0078 亿美元。</p>
<p>Clear Secure 最近增强其身份验证解决方案，展现出在高需求科技领域的强劲增长和创新。公司年收入增长 12%，预计盈利将上升 23.7%，其战略重点显而易见。他们最近与 Ochsner Health 合作，在医疗工作流程中部署 CLEAR1，突显了他们将先进技术无缝集成到日常运营中的承诺。这一举措不仅提升了安全性，还简化了患者和员工的访问，使 Clear Secure 在医疗领域的数字身份解决方案中处于领先地位——这一领域正处于技术颠覆的边缘。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Clear Secure 的动态。</li>
<li>通过查看我们的历史报告了解 Clear Secure 的业绩记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown"/></p>
<p>YOU 收入和支出明细截至 2026 年 3 月</p>
<h2>接下来该怎么办？</h2>
<ul>
<li>在这里发现 73 只美国高增长科技和人工智能股票的完整阵容。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，轻松监控您股票的所有重要指标。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，获取各市场无与伦比的股票分析。</li>
</ul>
<h2>准备探索其他投资风格吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

标普医疗保健服务 ETF - SPDR

PSTG

基因改革 ETF - ARK

<p>美国市场在过去一周下跌了 2.3%，但在过去一年中仍上涨了 13%，预计年均盈利增长为 16%。主要的高增长科技股票包括 Protagonist Therapeutics、Everpure 和 Clear Secure，这些公司都显示出强劲的收入和盈利增长。Protagonist 预计将实现盈利，年利润增长率为 40.85%，而 Everpure 则专注于增强人工智能基础设施。Clear Secure 在身份验证方面进行创新，预计收入增长 12%，盈利增长 23.7%。投资者可以探索 73 只高增长科技股票的名单，以寻找潜在机会</p>

<p>Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability, positioning themselves well amidst fluctuating market conditions.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场下跌了 2.3%，但在过去一年中仍上涨了 13%，预计年收益增长将达到 16%。在这种背景下，识别高增长科技股需要寻找那些展现出强大创新能力和适应能力的公司，使其在波动的市场环境中占据有利位置。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.02%</td>
<td>31.25%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.20%</td>
<td>27.96%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>30.23%</td>
<td>46.19%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ondas</td>
<td>35.55%</td>
<td>69.51%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.90%</td>
<td>48.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.76%</td>
<td>155.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>12.08%</td>
<td>99.98%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.02%</td>
<td>31.25%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>22.20%</td>
<td>27.96%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>30.23%</td>
<td>46.19%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Ondas</td>
<td>35.55%</td>
<td>69.51%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.90%</td>
<td>48.88%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.76%</td>
<td>155.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>12.08%</td>
<td>99.98%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 73 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of from the screener.</p>
<div class="lb-trans"><p>让我们深入探讨筛选器中的一些优质选择。</p>
</div><h2>Protagonist Therapeutics (PTGX)</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics (PTGX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Protagonist Therapeutics, Inc. is a discovery and development company based in the United States with a market capitalization of $6.29 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Protagonist Therapeutics, Inc. 是一家总部位于美国的发现与开发公司，市值为 62.9 亿美元。</p>
</div><p><strong>Operations:</strong> Protagonist Therapeutics focuses on biotechnology, generating revenue of $46.02 million from this segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> Protagonist Therapeutics 专注于生物技术，从该领域产生的收入为 4602 万美元。</p>
</div><p>Protagonist Therapeutics, poised for significant growth, is expected to transition from unprofitability to profitability within three years, with an anticipated annual profit growth of 40.85%. This shift is underscored by a robust revenue increase forecast at 23.6% annually, outpacing the US market's average of 10.4%. Recent FDA nods for rusfertide and ICOTYDE(TM) highlight its innovative edge in addressing complex medical conditions like polycythemia vera and plaque psoriasis, potentially setting new industry standards and bolstering its market position. Despite recent financial setbacks noted in its Q4 earnings report—where a net loss of $44.38 million was recorded—these strategic product advancements could catalyze a turnaround, enhancing its competitive stance in the biotech sector.</p>
<div class="lb-trans"><p>Protagonist Therapeutics 预计将在三年内从亏损转向盈利，年利润增长预期为 40.85%。这一转变得益于预计年收入增长 23.6%，超过美国市场平均 10.4% 的水平。最近，FDA 对 rusfertide 和 ICOTYDE(TM) 的批准突显了其在应对复杂医疗条件（如真性红细胞增多症和斑块性银屑病）方面的创新优势，可能设定新的行业标准并增强其市场地位。尽管在其第四季度财报中记录了 4438 万美元的净亏损，但这些战略产品的进展可能会催化转机，提升其在生物技术领域的竞争地位。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Protagonist Therapeutics stock in this health report.</li>
<li>Explore historical data to track Protagonist Therapeutics' performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>在本健康报告中解锁我们对 Protagonist Therapeutics 股票分析的全面见解。</li>
<li>在我们的历史部分探索历史数据，以跟踪 Protagonist Therapeutics 的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/fc7d3f36-7789-4a40-8892-bf2ab67f8e26/chart/earnings-and-revenue-growth"/></p>
<p>PTGX Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月 PTGX 的收益和收入增长</p>
</div><h2>Everpure (PSTG)</h2>
<div class="lb-trans"><h2>Everpure (PSTG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Everpure, Inc. specializes in data storage and management technologies, products, and services globally with a market capitalization of approximately $21.28 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Everpure, Inc. 专注于全球数据存储和管理技术、产品及服务，市值约为 212.8 亿美元。</p>
</div><p><strong>Operations:</strong> With a revenue of approximately $3.66 billion from its Computer Storage Devices segment, Everpure, Inc. focuses on delivering data storage and management solutions both in the U.S. and internationally.</p>
<div class="lb-trans"><p><strong>运营：</strong> Everpure, Inc. 从其计算机存储设备部门获得约 36.6 亿美元的收入，专注于在美国和国际上提供数据存储和管理解决方案。</p>
</div><p>Everpure's recent strategic initiatives underscore its commitment to enhancing AI infrastructure capabilities, crucial for maintaining competitiveness in the tech sector. With a focus on reducing complexity and cost in enterprise AI projects, Everpure introduced Evergreen//One for FlashBlade//EXA and the upcoming beta of Everpure Data Stream. These innovations are designed to streamline data handling from ingestion to inference, significantly accelerating time-to-result by automating data movement. This approach not only simplifies the operational aspect of AI deployments but also ensures high-performance standards are met consistently across large-scale applications, evidenced by FlashBlade//EXA's record-setting benchmark scores in SPECstorage Solution 2020 and MLPerf tests. By aligning with NVIDIA's modular STX reference architecture, Everpure is poised to meet the escalating demands of next-generation AI factories, ensuring that their solutions remain at the forefront of technology advancements while supporting sustainable growth.</p>
<div class="lb-trans"><p>Everpure 最近的战略举措强调了其增强人工智能基础设施能力的承诺，这对维持在科技行业的竞争力至关重要。Everpure 推出了 Evergreen//One for FlashBlade//EXA 和即将推出的 Everpure Data Stream 测试版，旨在减少企业人工智能项目的复杂性和成本。这些创新旨在简化从数据摄取到推理的数据处理，通过自动化数据移动显著加快结果时间。这种方法不仅简化了人工智能部署的操作方面，还确保在大规模应用中始终满足高性能标准，FlashBlade//EXA 在 SPECstorage Solution 2020 和 MLPerf 测试中的创纪录基准分数就是明证。通过与 NVIDIA 的模块化 STX 参考架构对齐，Everpure 准备满足下一代人工智能工厂日益增长的需求，确保其解决方案始终处于技术进步的前沿，同时支持可持续增长。</p>
</div><ul>
<li>Take a closer look at Everpure's potential here in our health report.</li>
<li>Assess Everpure's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更深入地了解 Everpure 的潜力。</li>
<li>通过我们的详细历史表现报告评估 Everpure 的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/63ddf8b4-b476-457f-9139-d84de0f609b7/chart/earnings-and-revenue-growth"/></p>
<p>PSTG Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>截至 2026 年 3 月 PSTG 的收益和收入增长</p>
</div><h2>Clear Secure (YOU)</h2>
<div class="lb-trans"><h2>Clear Secure (YOU)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Clear Secure, Inc. operates a secure identity platform under the CLEAR brand name primarily in the United States, with a market cap of approximately $7.13 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Clear Secure, Inc. 在美国主要运营一个安全身份平台，品牌名称为 CLEAR，市值约为 71.3 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its Secure Biometric Identity Verification segment, which contributed $900.78 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其安全生物识别身份验证部门产生收入，该部门贡献了 9.0078 亿美元。</p>
</div><p>Clear Secure, recently enhancing its identity verification solutions, demonstrates robust growth and innovation in high-demand tech sectors. With a 12% annual revenue increase and an anticipated 23.7% rise in earnings, the company's strategic focus is evident. Their recent partnership with Ochsner Health to deploy CLEAR1 across healthcare workflows underscores their commitment to integrating advanced technology seamlessly into everyday operations. This initiative not only boosts security but also streamlines patient and employee access, positioning Clear Secure at the forefront of digital identity solutions in healthcare—a sector ripe for technological disruption.</p>
<div class="lb-trans"><p>Clear Secure 最近增强其身份验证解决方案，展现出在高需求科技领域的强劲增长和创新。公司年收入增长 12%，预计盈利将上升 23.7%，其战略重点显而易见。他们最近与 Ochsner Health 合作，在医疗工作流程中部署 CLEAR1，突显了他们将先进技术无缝集成到日常运营中的承诺。这一举措不仅提升了安全性，还简化了患者和员工的访问，使 Clear Secure 在医疗领域的数字身份解决方案中处于领先地位——这一领域正处于技术颠覆的边缘。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Clear Secure.</li>
<li>Understand Clear Secure's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Clear Secure 的动态。</li>
<li>通过查看我们的历史报告了解 Clear Secure 的业绩记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/f0872d91-010c-4d66-8b62-49e7da1a57fb/chart/revenue-and-expenses-breakdown"/></p>
<p>YOU Revenue and Expenses Breakdown as at Mar 2026</p>
<div class="lb-trans"><p>YOU 收入和支出明细截至 2026 年 3 月</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该怎么办？</h2>
</div><ul>
<li>Discover the full array of 73 US High Growth Tech and AI Stocks right here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里发现 73 只美国高增长科技和人工智能股票的完整阵容。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，轻松监控您股票的所有重要指标。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，获取各市场无与伦比的股票分析。</li>
</ul>
</div><h2>Ready To Venture Into Other Investment Styles?</h2>
<div class="lb-trans"><h2>准备探索其他投资风格吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

当前值得关注的美国高增长科技股